Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...

Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

This was the stock's second consecutive day of losses.

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of $118 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The company will participate in ...

Featured here, the Balance Sheet for Bristol-Myers Squibb Company BDR, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 ...